An international team of investigators in the UK, Turkey, and elsewhere sequenced the genomes of nearly 100 MRSA isolates — a collection that showed widely variable toxicity profiles in their cell- and mouse-based assays. The team's analysis led to a genetic signature that appeared to coincide with the most pronounced toxicity patterns in the MRSA isolates. Those snippets of sequence subsequently proved useful for predicting which isolates would have high or low toxicity in a mouse model of MRSA infection.
Myriad Genetics has submitted to the US Food and Drug Administration the first module of its premarket approval application for BRACAnalysis as a companion test for AstraZeneca's breast cancer PARP inhibitor olaparib. The test is being used in two Phase III trials to pick out ovarian cancer patients who harbor BRCA mutations and as such are thought to be best responders to olaparib. Myriad filed an investigational device exemption application with the FDA less than a year ago to enable it to use BRACAnalysis in these studies.
A research team at Washington University School of Medicine in St. Louis plans to use an $8 million grant from the National Heart, Lung, and Blood Institute to conduct a large-scale analysis of genetic and lifestyle data from multi-ethnic cohorts. The scientists plan to examine data from more than 30 studies, including genomic information, common cardiovascular measures, and a range of lifestyle factors, to try to identify interactions between genetics and lifestyle that impact cardiovascular disease risk.
GenomeWeb and Myriad RBM invite you to a free online presentation by Matthew Albert of the Institut Pasteur on recent progress in personalized immune response monitoring.
Dr. Albert will share findings from the Milieu Interieur Project, a population-based study that aims to identify the genetic and environmental determinants of immune phenotype variance and establish a path towards personalized medicine.